Connect Biopharma is trading 10.3% up at $2.57 after reporting second-quarter 2026 results on August 12, including $2.8 million in milestone revenue and an EPS beat.
- Completed enrollment in Phase 2 Seabreeze STAT asthma and COPD studies; topline results are expected in September 2026.
- Reported cash runway of at least one year, despite a wider $17.3 million net loss.
- Broader risk-on sentiment may provide additional support as U.S. indexes rise.